Inflexion is pleased to announce it has exited its investment in Pharmaspectra, a leading global provider of medical affairs data and analytics to the pharmaceutical and biotech industry, to a listed trade buyer.
This sale follows strong continued exit momentum for Inflexion with nine exits announced during 2022 with a combined valuation of £2.5bn.
Inflexion has a long and successful history of investing in the healthcare and pharma services sectors. The exit of Pharmaspectra marks its sixth exit in the sector, generating an IRR of 25%.
Pharmaspectra hosts the world’s largest, continuously updated and integrated online repository of disseminated medical science information. This includes 16 million meeting presentations, 28 million publication abstracts and 417,000 clinical trials results. This data is used across the pharmaceutical sector where Pharmaspectra has an expansive and diverse customer base including 13 of the top 20 pharma companies.
Inflexion completed the buyout of Pharmaspectra in 2019 through its Enterprise Fund and drove significant growth of the business with the number of clients increasing by c.160%. Under Inflexion’s ownership, substantial investment was made into the growth of Pharmaspectra’s sales team, marketing and client services as well as in the launch of the company’s new product offering and technology platform. Inflexion also supported the international growth of the business including the build-out of the team in India and developing Pharmaspectra’s market entry strategy into China.
We are proud of the growth and development of Pharmaspectra during our stewardship. The business has significantly increased its number of clients whilst enhancing its product offering through an ambitious programme of digital enhancement and international expansion, all contributing towards significant client wins.
Pharmaspectra has seen significant growth over the past few years with the support of Inflexion. The business has invested in both its digital platform as well as its international operations, helping to attract a number of major new global clients. I look forward to continuing our growth journey.